J. W. Chapman

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

Clifford A. Hudis, William E. Barlow, Joseph P. Costantino et al. · Journal of Clinical Oncology · 2007 · 885 citations · Full text

Medicine, Biostatistics, Oncology +17

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

Edward L. Korn, Ping-Yu Liu, Sandra J. Lee et al. · Journal of Clinical Oncology · 2008 · 700 citations · Full text

Medicine, Biostatistics, Oncology +16

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Lynne I. Wagner, Fengmin Zhao, Paul E. Goss et al. · Breast Cancer Research and Treatment · 2018 · 95 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy

James N. Ingle, Fang Xie, Matthew J. Ellis et al. · Cancer Research · 2016 · 76 citations · Full text

Medicine, Genetics, Molecular Genetics +17

A multicenter international controlled comparison of two dosage regimens of misoprostol with cimetidine in treatment of gastric ulcer in outpatients

Daniel Rachmilewitz, J. W. Chapman, Paul A. Nicholson · Digestive Diseases and Sciences · 1986 · 65 citations

Medicine, Pharmacology, Pharmacotherapy +10